Compare Enovix Corporation (ENVX) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Enovix Corporation trades at $2.41 (market cap $550.82M), while GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 56.4× Enovix Corporation's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | GEHC | |
|---|---|---|
Market Cap | $550.82M | $31.07B |
Volume | 5,977,872 | 3,443,020 |
Sector | Industrials | Health |
52-Week High | $13.19 | $88.16 |
52-Week Low | $2.44 | $59.48 |
Typical Hold Time | 11 Days | — |
Enterprise Value | $612.51M | $39.53B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.51, down 3.09% on the day, reflecting bearish technical signals and negative profitability. The company reported a net loss of -$156.74M in 2025, with revenue of $31.82M, while recent quarterly EPS has consistently beaten expectations. Key developments include a CEO transition in August 2026 and expansion of drone battery capacity in South Korea.
Despite deep losses and cash burn, analyst consensus remains bullish with a $9.60 price target, citing potential in defense and smartphone battery markets. Risks include high cash burn, leadership changes, and competitive pressures. The stock's outlook hinges on successful commercialization and margin improvement.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
